SCHEMBL457072

SCHEMBL457072

O=C1C(=NNC(=S)Nc2ccc(F)cc2)Nc2ccc(Br)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPK1 P28482 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 3/20 0.43
GAA P10253 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TGM2 P21980 1/20 0.41
CES1 P23141 1/20 0.41
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
HTT P42858 1/20 0.39
CA1 P00915 3/20 0.38
CA9 Q16790 3/20 0.38
CA12 O43570 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL454941 0.91 ALDH1A1 (0.46) MAPTKMT2AMEN1MAPK1LMNA
SCHEMBL455908 0.85 RRM1 (0.44) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL469862 0.84 KDR (0.48) MAPTKMT2AMEN1MAPK1LMNA
SCHEMBL2877863 0.84 ALDH1A1 (0.46) MAPTKMT2AMEN1MAPK1LMNA
SCHEMBL455315 0.82 KDR (0.52) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL31492064 0.78 KDR (0.50) MAPTKMT2AMEN1MAPK1LMNA
SCHEMBL469859 0.77 CA1 (0.50) MAPTALDH1A1TGM2CES1CA1
SCHEMBL13008097 0.74 KDR (0.54) MAPTKMT2AMAPK1ALDH1A1GAA
SCHEMBL469845 0.73 AGTR1 (0.57) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL10085721 0.73 KDR (0.52) MAPTALDH1A1TGM2CES1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed